Transient receptor potential cation channel subfamily V member 3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Transient receptor potential cation channel subfamily V member 3 shows clinical signal disease relevance led by neuropathic pain. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q8NET8. Start with neuropathic pain, then reuse UniProt Q8NET8 as the stable protein anchor across project notes and exports.
Start with neuropathic pain, then reuse UniProt Q8NET8 as the stable protein anchor across project notes and exports.
Transient receptor potential cation channel subfamily V member 3 shows clinical signal disease relevance led by neuropathic pain. 1 linked drug remains visible in the same block.
Start review with neuropathic pain because it currently carries clinical signal support. Linked drugs include GRC-15300. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTransient receptor potential cation channel subfamily V member 3
Review this target as Transient receptor potential cation channel subfamily V member 3, mapped to UniProt Q8NET8. Sequence length is 790 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Transient receptor potential cation channel subfamily V member 3 as ChEMBL target CHEMBL5522, mapped to UniProt Q8NET8. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Transient receptor potential cation channel subfamily V member 3 is the right protein anchor across sources, using UniProt Q8NET8 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why neuropathic pain is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Transient receptor potential cation channel subfamily V member 3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q8NET8 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Transient receptor potential cation channel subfamily V member 3 |
| UniProt Accession | Q8NET8 |
| Component Type | Protein |
| Sequence Length | 790 aa |
Transient receptor potential cation channel subfamily V member 3
Review this target as Transient receptor potential cation channel subfamily V member 3, mapped to UniProt Q8NET8. Sequence length is 790 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Transient receptor potential cation channel subfamily V member 3 shows clinical signal disease relevance led by neuropathic pain.
Start review with neuropathic pain because it currently carries clinical signal support. Linked drugs include GRC-15300. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3696391 | 7.1 | IC50 | 80.0 | Preclinical |
| CHEMBL3696410 | 7.1 | IC50 | 80.0 | Preclinical |
| CHEMBL3692308 | 6.96 | IC50 | 110.0 | Preclinical |
| CHEMBL3692305 | 6.92 | IC50 | 120.0 | Preclinical |
| CHEMBL3696433 | 6.92 | IC50 | 120.0 | Preclinical |
| CHEMBL3696452 | 6.92 | IC50 | 120.0 | Preclinical |
| CHEMBL3696448 | 6.89 | IC50 | 130.0 | Preclinical |
| CHEMBL3692284 | 6.85 | IC50 | 140.0 | Preclinical |
| CHEMBL3692310 | 6.85 | IC50 | 140.0 | Preclinical |
| CHEMBL3696392 | 6.85 | IC50 | 140.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 39 | 240 | 6.0 |
| single protein format | 8 | 7 | 5.4 |
| assay format | 3 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 0 | — |